Open-label, single ascending dose and multiple single dose study in healthy volunteers to evaluate the safety and pharmacokinetics of BIO 300 Oral Powder (BIO 300). The single ascending dose study consists of 4 ascending dose cohorts and the multiple single dose study consists of a single dose given daily for 6 consecutive days.

开始日期2020-12-08

申办/合作机构

Humanetics Corp.

[+1]

NCT04482595 / Recruiting临床2期

A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 Patients

This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe COVID-19-related illness and continue to experience post-acute respiratory complications associated with Long-COVID after discharge. Patients will be randomized 1:1 to receive BIO 300 or placebo.

开始日期2020-11-11

申办/合作机构

Humanetics Corp.

[+2]

100 项与 Genistein 相关的临床结果

登录后查看更多信息

100 项与 Genistein 相关的转化医学

登录后查看更多信息

100 项与 Genistein 相关的专利（医药）

登录后查看更多信息

11,829

项与 Genistein 相关的文献（医药）

2024-12-01·Molecular biology reports

Oxidative stress in Alzheimer’s disease: current knowledge of signaling pathways and therapeutics

Review

作者: Sharma, Prajjwal ; Singh, Sunil K ; Dhapola, Rishika ; Beura, Samir K ; HariKrishnaReddy, Dibbanti

Alzheimer's disease's pathophysiology is still a conundrum. Growing number of evidences have elucidated the involvement of oxidative stress in the pathology of AD rendering it a major target for therapeutic development. Reactive oxygen species (ROS) generated by altered mitochondrial function, dysregulated electron transport chain and other sources elevate aggregated Aβ and neurofibrillary tangles which further stimulating the production of ROS. Oxidative stress induced damage to lipids, proteins and DNA result in neuronal death which leads to AD. In addition, oxidative stress induces apoptosis that is triggered by the modulation of ERK1/2 and Nrf2 pathway followed by increased GSK-3β expression and decreased PP2A activity. Oxidative stress exaggerates disease condition by interfering with various signaling pathways like RCAN1, CREB/ERK, Nrf2, PP2A, NFκB and PI3K/Akt. Studies have reported the role of TNF-α in oxidative stress stimulation that has been regulated by drugs like etanercept increasing the level of anti-oxidants. Other drugs like pramipexole, memantine, carvedilol, and melatonin have been reported to activate CREB/RCAN1 and Nrf2 pathways. In line with this, epigallocatechin gallate and genistein also target Nrf2 and CREB pathway leading to activation of downstream pathways like ARE and Keap1 which ameliorate oxidative stress condition. Donepezil and resveratrol reduce oxidative stress and activate AMPK pathway along with PP2A activation thus promoting tau dephosphorylation and neuronal survival. This study describes in detail the role of oxidative stress in AD, major signaling pathways involving oxidative stress induced AD and drugs under development targeting these pathways which may aid in therapeutic advances for AD.

2024-12-01·Applied microbiology and biotechnology

Characterization and stabilization of GluLm and its application to deglycosylate dietary flavonoids and lignans

Article

作者: Curiel, José Antonio ; Langa, Susana ; de la Bastida, Ana Ruiz ; Peirotén, Ángela ; Landete, José María

Abstract:

This study describes the characterization of the recombinant GH3 aryl-β-glucosidase “GluLm” from Limosilactobacillus mucosae INIA P508, followed by its immobilization on an agarose support with the aim of developing an efficient application to increase the availability and concentration of flavonoid and lignan aglycones in a vegetal beverage. In previous studies, heterologous GluLm-producing strains demonstrated a great capacity to deglycosylate flavonoids. Nevertheless, the physicochemical properties and substrate spectrum of the enzyme remained unknown up to now. A high production of purified GluLm was achieved (14 mg L−1). GluLm exhibited optimal activity at broad ranges of pH (5.0–8.0) and temperature (25–60°C), as well as high affinity (Km of 0.10 mmol L−1) and specific constant (86554.0 mmol L−1 s−1) against p-nitrophenyl-β-D-glucopyranoside. Similar to other GH3 β-glucosidases described in lactic acid bacteria, GluLm exhibited β-xylosidase, β-galactosidase, and β-fucosidase activities. However, this study has revealed for the first time that a GH3 β-glucosidase is capable to hydrolyze different families of glycosylated phenolics such as flavonoids and secoiridoids. Although it exhibited low thermal stability, immobilization of GluLm improved its thermostability and allowed the development of a beverage based on soybeans and flaxseed extract with high concentration of bioactive isoflavone (daidzein, genistein), lignan (secoisolariciresinol, pinoresinol, and matairesinol), and other flavonoid aglycones.

Key points:

• Limosilactobacillus mucosae INIA P508 GluLm was purified and biochemically characterized• Immobilized GluLm efficiently deglycosylated flavonoids and lignans from a vegetal beverage• A viable application to produce vegetal beverages with a high content of aglycones is described

2024-06-01·Food chemistry

Flavonoid diversity in bitter and debittered seeds of Andean lupin (Lupinus mutabilis Sweet)

Article

作者: Repo-Carrasco-Valencia, Ritva ; Cortés-Avendaño, Paola ; Tian, Ye ; Yang, Baoru ; Suomela, Jukka-Pekka ; Glorio-Paulet, Patricia

Seeds of ten Andean lupin (Lupinus mutabilis Sweet) ecotypes were collected from different regions of Peru and treated with an aqueous debittering method. Both untreated and treated seeds were analyzed by using LC-MS to investigate flavonoid profiles of different ecotypes and impact of debittering process on these compounds. Thirteen isoflavones (mainly as glycosides of genistein and methoxy-genistein) and eight flavones (glycosylated apigenins and methyl-luteolins) were characterized as the main flavonoids in the seed samples. The untreated lupin seeds contained 187-252 mg/100 g (dry weight) of flavonoids. The main difference among lupin ecotypes was observed in the levels of genistein-malonylhexoside, methoxy-genistein-malonylhexoside, and methyl-luteolin-malonylhexoside. After the debittering treatment, the total flavonoid content in the seeds was decreased to 125-203 mg/100 g dry weight, the aglycones of genistein, methoxy-genistein, and methyl-luteolin being the key distinguishing compounds of ecotypes. The aqueous treatment was effective in degrading flavonoid glycosides and releasing the corresponding aglycones.

项与 Genistein 相关的新闻（医药）

2024-05-31

·BioSpace

Humanetics Corporation to Present at the 2024 BIO International Convention in San Diego

MINNEAPOLIS--(BUSINESS WIRE)-- Humanetics Corporation, a clinical-stage specialty pharmaceutical company developing radioprotectant drugs for warfighters and cancer patients, is presenting a corporate overview and details on its promising lead radioprotective drug candidate, BIO 300, at the prestigious Biotechnology Innovation Organization (BIO) International Convention in San Diego, CA next week. This convention, known for its global reach and influence, provides a platform for industry leaders to showcase their innovations. Ronald J. Zenk, Chief Executive Officer, will present this information on Monday, June 3, 2024 (1:30 pm Company Presentation Theatre 3). About BIO 300 Humanetics is pioneering the development of a groundbreaking radioprotectant drug, BIO 300. This innovative medical countermeasure, with its dual application in military and medical contexts, is designed to protect normal tissues from radiation damage, setting it apart from other drug candidates. BIO 300 has received considerable attention, funding, and research from the Department of Defense (DOD) for its potential to mitigate the harmful effects of radiation among warfighters and civilians in the event of a nuclear attack or radiological incident. The need for such a product has escalated significantly, given current world events. Humanetics is currently working under a contract with DOD to position BIO 300 for Emergency Use Authorization to provide the product to warfighters across the globe. BIO 300 is also indicated for use as a new class of drug to improve outcomes in cancer patients who received first-line radiotherapy with or without concurrent chemotherapy. These patients suffer from a myriad of unintended side effects, which can reduce the efficacy of treatment or result in serious toxicities. BIO 300 protects normal tissues, improving therapeutic outcomes. BIO 300 is currently undergoing phase 2 clinical trials, marking a significant milestone in its development journey. The trials aim to evaluate its effectiveness in preventing normal tissue injury from cancer radiotherapy and reducing lung damage in COVID-19 long-haul patients. Administered as an oral liquid nanosuspension, BIO 300 has shown promising potential to minimize radiation damage in normal tissues without compromising the effectiveness of radiation therapy against the tumor. These positive results from the Phase 1/2a clinical trial in non-small cell lung cancer patients undergoing chemoradiotherapy further bolster BIO 300’s prospects, indicating its safety and potential for positive clinical outcomes. About Humanetics Corporation Humanetics is an advanced clinical-stage specialty pharmaceutical company engaged in the development and commercialization of radioprotectant drugs to prevent harm caused by exposure to ionizing radiation; for protective use in cancer radiation therapy; and to guard against the long-term damaging effects of COVID-19. For more information, visit humaneticscorp.com. View source version on businesswire.com: Contacts Ronald J. Zenk Humanetics Corporation 952-400-0400 Source: Humanetics Corporation View this news release online at:

放射疗法临床2期

2024-02-07

·Business Wire

Humanetics Corporation to Present at Investor and Partnering Conferences

MINNEAPOLIS--( BUSINESS WIRE )--Humanetics Corporation (Humanetics), a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies, has announced that it will present and participate in several investor and partnering conferences in February. Ronald J. Zenk, Chief Executive Officer at Humanetics, along with members of management and the board of directors, will present an overview of the company and hold one-on-one meetings with potential investors and partners at the following conferences: Emerging Growth Conference, February 7-8, 2024 (virtual) The Emerging Growth Conference features companies in a wide range of growth sectors with strong management teams, innovative products and services, and focused strategy and execution. The potential audience includes tens of thousands of individual and institutional investors, investment advisors, and analysts. For more information about the Emerging Growth Conference, visit Emerging Growth Conference - EmergingGrowth.com . Presentation Date: Wednesday, February 7, 2024 Presentation Time: 1:45-2:15 PM Eastern Time Webcast link: https://goto.webcasts.com/starthere.jsp?ei=1648929&tp_key=d1cd45a6dc&sti=humanetics Oppenheimer 34 th Annual Healthcare Life Sciences Conference, February 13-14, 2024 (virtual) This conference provides investors with a broad spectrum of public and private healthcare companies spanning all major sectors of the healthcare industry: bio and specialty pharmaceuticals; biotechnology; medical devices; life science tools and diagnostics; healthcare information technology and distribution; and healthcare providers and servicers. Presentation date: Tuesday, February 13, 2024 Presentation time: 3:20-3:50 PM Eastern Time Webcast link: https://wsw.com/webcast/oppenheimer33/humane/3223292 BIO CEO & Investor Conference , February 26-27, 2024, New York, NY Sponsored by the Biotechnology Industry Organization (BIO), the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded, late-stage private biotech companies. Event registration: Register for the BIO CEO & Investor Conference . Presentation date: Tuesday, February 26, 2024 Presentation time: 10:15 AM Eastern Time Presentation location: New York Marriott Marquis, Royale Room 17 th Annual European Life Sciences CEO Forum , February 28-29th, 2024, Zurich, Switzerland; March 6-8, 2024 (virtual) The conference is expected to include 400+ delegates from all life sciences sectors, with a target audience that includes corporate and financial investors/partners, banks, and advisors. There will be a global company showcase of 50+ presentations by established public, private, emerging, and seed companies offering innovative solutions and seeking investment and partnering opportunities. This will include a limited number of live presentations on dedicated presentation tracks, alongside virtual company showcases available on demand during the virtual week. For more information, visit About the 17th Annual European Life Sciences CEO Forum (sachsforum.com) . Presentation location: Zurich Hilton Zurich Airport Hotel About Humanetics Corporation and BIO 300 Humanetics is developing a new drug candidate, BIO 300, as a medical countermeasure to prevent radiation damage. BIO 300 has received considerable attention, funding, and research from the Department of Defense (DOD) for its potential to mitigate the harmful effects of radiation among warfighters and civilians in the event of a nuclear attack or radiological incident. Given current world events, the need for such a product has escalated significantly. Humanetics is currently working under a contract with DOD to position BIO 300 for Emergency Use. BIO 300 is a new class of drug focused on improving outcomes in cancer patients who received first-line radiotherapy with or without concurrent chemotherapy. These patients suffer from a myriad of unintended side effects, which can reduce the efficacy of treatment or result in serious toxicities. BIO 300 acts to protect normal tissues, improving the therapeutic outcome. BIO 300 is being evaluated in phase 2 clinical trials to prevent normal tissue injury from cancer radiotherapy and reduce lung damage in COVID-19 long-haul patients. It is self-administered by patients in these trials as an oral liquid nanosuspension. It has shown the potential to minimize radiation damage in normal tissues without impacting the effectiveness of the radiation therapy against the tumor. BIO 300 was the subject of an early-stage trial in non-small cell lung cancer patients undergoing chemoradiotherapy. It was found to be safe, with results pointing to positive clinical outcomes. Humanetics licensed BIO 300 from the United States Department of Defense (DOD), where it was discovered as a potent radioprotectant for warfighters on the battlefield. Its use in cancer patients is highly aligned with its military use, as it serves in both cases to protect normal tissues from radiation damage.

临床2期放射疗法

2024-01-28

·AIDD Pro

【第一百一十二期】AI+药物研发领域一周资讯

前言AIDD Pro 根据国内外各大网站以及人工智能药物设计主流新闻网站及公众号，从 AIDD会议、AIDD招聘，重大科研进展、行业动态、最新报告发布等角度，分析挖掘了每周人工智能辅助药物设计领域所发生的、对领域技术发展产生重大推动作用的事件，旨在帮助 AIDD领域研究人员和业内人士及时追踪最新科研动态、洞察前沿热点。如果您觉得符合以上要求的内容我们有遗漏或者更好建议，欢迎后台留言。科研进展2024年1月26日【药物偶联物】J. Med. Chem. | 肽-药物偶联物：下一代肽治疗的新兴方向2024年1月26日【SARS-CoV-2】J. Chem. Inf. Model. | 类黄酮支架对SARS-CoV-2 3CLpro的抑制活性：来自计算和实验研究的见解2024年1月25日【药物发现】J. Med. Chem. | 微循环：加速药物发现的集成和自动化平台2024年1月25日【机器学习】J. Chem. Inf. Model. | 蛋白质分类-基于自由能计算和机器学习方法的蛋白质结合亲和力2024年1月25日【蛋白质结构预测】ACS Omega | PSSP-MFFNet：蛋白质二级结构预测的多特征融合网络2024年1月24日【人工智能】J. Chem. Inf. Model. | AutoMolDesigner for Antibiotic Discovery：一个基于人工智能的小分子抗生素自动设计开源软件具体信息，请滑动下方文字1.【药物偶联物】基于肽科学的最新进展，药物化学家已经开发出一种称为肽-药物偶联物的混合类生物偶联物，与肽和独立的小分子相比，它显示出更高的功效。在这个观点中，我们讨论了如何利用协同肽和小分子的偶联来克服复杂的疾病状态和耐药机制，这些疾病状态和耐药机制由于其多组分活性而无法通过当代治疗。我们强调肽-药物偶联物如何显示出与抗体-药物偶联物相似的多因素治疗机制，但也显示出改进的治疗特性，如不太严重的脱靶效应和具有更大位点特异性的偶联策略。讨论了多肽-药物偶联设计和优化的许多考虑因素，如多肽/小分子配对和化学选择性化学。我们还研究了几种肽-药物偶联物系列，它们对复杂的疾病状态(如神经退行性疾病和炎症)以及具有已建立的耐药机制的病毒和细菌靶点显示出显著的活性。链接网址：https://pubs-acs-org.libproxy1.nus.edu.sg/doi/10.1021/acs.jmedchem.3c01835DOI:https://doi-org.libproxy1.nus.edu.sg/10.1021/acs.jmedchem.3c018352.【SARS-CoV-2】由于缺乏有效的抗病毒药物治疗，新冠肺炎疫情的出现已成为一个全球性问题。黄酮类化合物是一类通过抑制主要蛋白酶(3CLpro)对SARS-CoV-2具有抗病毒活性的植物次生代谢物。在本研究中，研究了从天然来源和半合成方法中获得的22种黄酮类化合物对SARS-CoV-2 3CLpro的抑制活性以及对Vero细胞的细胞毒性。利用分子动力学模拟研究了蛋白质与配体的相互作用。此外，还进行了QSAR分析，以阐明结构对生物活性的影响。因此，体外研究表明，四种黄酮类化合物，即tectochrysin(7)， 6″，6″-dimethylchromeno-[2″，3″:7,8]-flavone (9)， panduratin A(19)和genistein(20)，与标准黄酮类化合物黄芩素相比，具有更高的蛋白酶抑制活性。最后，我们的研究结果表明，在Millettia brandisiana中发现的异黄酮染料木素(genistein, 20)具有进一步开发作为SARS-CoV-2 3CLpro抑制剂的潜力。链接网址：https://pubs-acs-org.libproxy1.nus.edu.sg/doi/10.1021/acs.jcim.3c01477DOI：https://doi-org.libproxy1.nus.edu.sg/10.1021/acs.jcim.3c014773.【药物发现】我们在此描述了一个模块化技术平台的开发和应用，该平台结合了基于平板的微尺度化学、自动净化、原位定量和机器人液体处理的最新进展，能够快速获取已经格式化用于分析的高质量化学物质。利用微尺度化学，消耗最少的化学物质，该平台不仅高效，而且遵循绿色化学原则。通过重新定位现有的高通量分析技术，该平台可以在每个学习周期中生成每组化合物的完整相关数据包。化学和性质空间的多参数探索由此由主动学习模型驱动。增强的化合物优化过程在前所未有的时间框架内为药物发现项目产生知识。链接网址：https://pubs-acs-org.libproxy1.nus.edu.sg/doi/10.1021/acs.jmedchem.3c02029DOI：https://doi-org.libproxy1.nus.edu.sg/10.1021/acs.jmedchem.3c020294.【机器学习】理解大脑中神经元连接的复杂现象是神经科学领域的一大研究课题。在果蝇(Drosophila melanogaster)中，已确定dprp - dip相互作用组在这一过程中发挥重要作用。然而，实验数据表明，仅仅是有限的复合物子集，即总共231种复合物中的57种，表现出很强的结合亲和力。在这项工作中，我们试图使用最先进的方法，包括具有几何路线和机器学习(ML)技术的标准结合自由能计算，来确定结合亲和力差异背后的残留物水平分子基础。我们利用统计力学模拟确定了两种复合物的结合亲和力，实现了实验数据的良好再现。此外，我们预测了另外两个低亲和力配合物的结合自由能，而没有实验估计，同时确定了结合的关键残基。此外，通过使用机器学习算法、线性判别分析和随机森林，我们在区分强(同源)和弱(非同源)结合物方面取得了显著的准确性，高达0.99。所提出的机器学习方法包含易于转移的输入特征，使其广泛应用于任何相互作用组，同时促进对结合相互作用至关重要的关键残基的识别。对13个不同物种的相似蛋白家族进行了预测。我们的机器学习模型在这些额外的数据集上表现出值得称赞的性能，展示了其跨物种屏障的可靠性和鲁棒性。链接网址：https://pubs-acs-org.libproxy1.nus.edu.sg/doi/10.1021/acs.jcim.3c01586DOI：https://doi-org.libproxy1.nus.edu.sg/10.1021/acs.jcim.3c015865.【蛋白质结构预测】蛋白质二级结构预测(PSSP)是现代生物信息学研究的一项基础任务，对揭示蛋白质的功能机制具有重要意义。为了提高PSSP的准确性，通常使用氨基酸序列产生的各种一般和基本特征来预测二级结构。本文提出了基于深度学习的PSSP多特征融合网络PSSP- mffnet，该网络将多视图深度学习架构与多序列比对(multiple sequence alignment, MSA) Transformer相结合，有效捕获蛋白质序列的全局和局部特征。在实践中，psp - mffnet采用多特征融合策略，将蛋白质序列产生的不同特征进行融合，包括MSA、序列信息、进化信息和隐藏状态信息。此外，我们使用MSA Transformer在输入MSA中交错行和列注意。在特征融合后，采用卷积神经网络和长短期记忆网络的混合网络结构提取高级特征。此外，我们还引入了一个变压器编码器来增强提取的高级特征。独立测试的对比实验结果表明，PSSP- mffnet具有出色的泛化能力，在包括CASP12、CASP13、CASP14、TEST2018和CB513在内的公共基准测试中，PSSP- mffnet平均优于其他最先进的PSSP模型1%。我们的方法有助于更好地理解蛋白质的生物学功能，这对药物发现、疾病诊断和蛋白质工程具有重要意义。链接网址：https://pubs-acs-org.libproxy1.nus.edu.sg/doi/10.1021/acsomega.3c10230DOI：https://doi-org.libproxy1.nus.edu.sg/10.1021/acsomega.3c102306.【人工智能】发现具有新型化学型的小分子抗生素是解决抗生素耐药性的重要策略之一。尽管已经报道了相当数量的致力于分子设计的计算工具，但在专门为小分子抗生素发现开发的整体和高效工具方面存在缺陷。为了解决这个问题，我们报告了AutoMolDesigner，一个专门用于小分子抗生素设计的计算建模软件。它是一个广义的框架，包括两个功能模块，即生成深度学习的分子生成和基于机器学习的自动抗菌活性/特性预测，其中单独训练的模型和策划的数据集对于基于全细胞的抗生素筛选和设计是开箱即用的。它是开源的，因此允许合并新特性以灵活使用。与大多数基于Linux和命令行的软件程序不同，该应用程序配备了基于qt的图形用户界面，可以在具有多种操作系统的个人计算机上运行，使实验科学家更容易使用。该软件和相关材料可在GitHub (https://github.com/taoshen99/AutoMolDesigner)和Zenodo (https://zenodo.org/record/10097899)上免费获得。链接网址：https://pubs-acs-org.libproxy1.nus.edu.sg/doi/10.1021/acs.jcim.3c01562DOI：https://doi-org.libproxy1.nus.edu.sg/10.1021/acs.jcim.3c01562上下滚动查看更多药企动态2023年1月27日【新时代药业】新时代药业利妥昔单抗生物类似药申报上市2023年1月26日【赛诺菲】首个！度普利尤单抗新适应症获FDA批准，治疗1至11岁EoE患儿2023年1月26日【辉瑞】重磅口服偏头痛新药！辉瑞CGRP受体拮抗剂在华获批上市2023年1月26日【强生】强生EGFR/c-MET双抗组合疗法在华申报上市2023年1月25日【药明生物】药明生物推出全新细胞株平台WuXia ADCC PLUS™赋能合作伙伴研发生产高ADCC活性无岩藻糖基化抗体2023年1月25日【CG Oncology】今年首家生物技术公司成功IPO，融资3.8亿美金，专注于基因疗法2023年1月24日【药明合联】药明合联与Celltrion就抗体偶联药物综合服务达成合作各动态具体信息，请滑动下方文字1.【新时代药业】1月27日，CDE网站显示，山东新时代药业的利妥昔单抗生物类似药上市申请获受理。原研利妥昔单抗来自罗氏旗下Genentech，是一种靶向CD20的治疗性单克隆抗体，1997年首次获FDA批准上市，并于2000年进入中国市场，商品名为美罗华。2013年原研利妥昔单抗注射液中国专利到期，多家国内外制药企业加入其生物类似药的研发。链接网址请戳我2.【赛诺菲】1月26日，赛诺菲/再生元共同宣布，FDA已批准Dupixent（度普利尤单抗）新适应症，用于1至11岁嗜酸性粒细胞性食管炎（EoE）患者的治疗。新闻稿指出，Dupixent是目前美国首款也是唯一一款用于治疗这些患者的药物。链接网址请戳我3.【辉瑞】1月26日，辉瑞宣布，其偏头痛药物硫酸瑞美吉泮口崩片（Rimegepant）在华获批上市，用于成年人有或无先兆偏头痛的急性治疗。Rimegepant是全球首个且唯一个采用专利口崩片技术的降钙素基因相关肽(CGRP)受体拮抗剂,2020年2月首次获FDA批准用于成人急性偏头痛的治疗，2021年5月，又扩展新适应症，用来预防成人发作性偏头痛。链接网址请戳我4.【强生】1月26日，CDE网站显示，强生两款创新药物EGFR/c-MET双抗埃万妥单抗（amivantamab）以及三代EGFR抑制剂兰泽替尼片（Lazertinib）上市申请均获药监局受理，推测申报适应症为二者联合治疗EGFR突变局部晚期或转移性非小细胞肺癌（NSCLC）患者。链接网址请戳我5.【药明生物】1月25日，全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物宣布推出全新哺乳动物细胞株构建技术平台WuXiaADCC PLUSTM。该平台为高效、高产量、高ADCC活性的无岩藻糖基化抗体开发和生产平台。链接网址请戳我6.【CG Oncology】1月25日，CG Oncology成为首家于 2024 年 IPO的生物科技公司，首日股价大涨96%，市值达到22.5亿美元。值得注意的是，公司通过此次IPO发售中募集了3.8亿美元，超出原先2亿美元的预期。一些行业媒体指出，CG Oncology公司的表现可能成为今年IPO市场的晴雨表。链接网址请戳我7.【药明合联】1月24日，药明合联与韩国生物制药公司Celltrion共同宣布签署合作备忘录（MOU），为包括抗体偶联药物（ADC）在内的生物偶联药开发和生产提供全面的综合服务。链接网址请戳我上下滚动查看更多会议信息2024年2月28-29日举办AntibodyChina 第七届抗体药物深度聚焦峰会2024年3月21-22日上海恺默信息咨询有限公司举办SIT 2024第六届小分子药物创新与合作大会2024年3月21-22日上海恺默信息咨询有限公司举办PDD 2024多肽药物产业发展大会2024年4月18-19日举办第四届I-RNA小核酸药物深度聚焦峰会2024年6月27-28日举办上海求实医药咨询有限公司ING 2024第七届免疫及基因治疗论坛各会议具体详情和参会方式，请滑动下方文字AntibodyChina 第七届抗体药物深度聚焦峰会会议时间：2024年2月28-29日会议地点：上海会议主旨：峰会议题跨越抗体药物研发的最前沿，追踪最新的临床进展，致力于打破行业的封闭循环，破除行业内卷，助推创新多元发展！一切尽在抗体药物的年度产业大会！链接网址请戳我SIT 2024第六届小分子药物创新与合作大会主办方：上海恺默信息咨询有限公司会议时间：2024年3月21日-22日会议地点：上海会议主旨：峰会议题跨越小分子药物研发的热点领域，一览当下化学创新药研发新动向，致力于打破行业的封闭循环，破除行业内卷，助推创新多元发展！一切尽在小分子药物的年度产业大会！链接网址请戳我PDD 2024多肽药物产业发展大会主办方：上海恺默信息咨询有限公司会议时间：2024年3月21日-22日会议地点：上海会议主旨：共谈多肽减重药物、多肽药物的法规与申报、开发案例与趋势、CMC 各个环节中的难点与挑战。力求为多肽企业致力于多肽药物研究的专家及科研人员提供一个深度的思想碰撞及经验分享平台。链接网址请戳我第四届I-RNA小核酸药物深度聚焦峰会会议时间：2024年4月18日-19日会议地点：苏州会议主旨：破解递送挑战与CMC难点，汇聚最新临床进展与热门研发方向；构建小核酸药物专属交流平台，打造产业闭环，推动国产小核酸药物产业化进程。链接网址请戳我ING 2024第七届免疫及基因治疗论坛主办方：上海求实医药咨询有限公司会议时间：2024年6月27日-28日会议地点：北京会议主旨：聚焦CGT领域开发的核心问题，破除技术壁垒，推动产业不断前进，开启生物医药产业下一个风口！链接网址请戳我上下滚动查看更多版权信息本文内容均由小编收集于公开的各个网络平台，发布的目的仅为了方便大家一站式了解AIDD行业信息，并未对发布源头进行真实性验证。如您发现相关信息有任何版权侵扰或者信息错误，请及时联系AIDD Pro（请添加微信号sixiali_fox59）进行删改处理。原创内容未经授权，禁止转载至其他平台。有问题可发邮件至sixiali@stonewise.cn关注我，更多资讯早知道↓↓↓

临床结果临床1期紧急使用授权

100 项与 Genistein 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11680	Genistein	-	DB01645

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肺损伤	临床2期	美国	Humanetics Corp.	2022-04-27
肺纤维化	临床2期	美国	Humanetics Corp.	2020-11-11
骨质疏松症	临床2期	中国	西安恒泰本草科技有限公司	2017-04-11
白血病	临床2期	加拿大	CHU Sainte-Justine	2015-07-01
晚期恶性实体瘤	临床2期	加拿大	Uman Pharma, Inc.	2012-11-01
非小细胞肺癌	临床2期	加拿大	Uman Pharma, Inc.	2012-11-01
前列腺腺癌	临床2期	美国	National Cancer Institute	2011-12-01
腺癌	临床2期	瑞典	Axcentua Pharmaceuticals AB	2010-11-01
乳腺癌	临床2期	美国	National Cancer Institute	2006-01-01
膀胱癌	临床2期	-	National Cancer Institute	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02624388 (UVA-Gen001, CTgov)	临床2期	霍奇金淋巴瘤 \| 急性淋巴细胞白血病 \| 肾母细胞瘤 ... 更多	4	Placebo+Genistein (Arm A: Genistein Followed by Placebo)	憲遞簾艱鏇鬱蓋憲蓋鏇(窪願獵範觸積餘廠糧網) = 鹽顧壓鹹範選鑰鑰鑰鑰顧窪齋簾繭齋淵壓憲鬱 (鬱憲顧選獵範網壓遞襯, 願選鬱積艱餘築鑰獵糧 ~ 憲獵築艱獵襯獵鑰繭選) 更多	-	2024-05-06
NCT02624388 (UVA-Gen001, CTgov)	临床2期	霍奇金淋巴瘤 \| 急性淋巴细胞白血病 \| 肾母细胞瘤 ... 更多	4	Placebo+Genistein (Arm B: Placebo Followed by Genistein)	憲遞簾艱鏇鬱蓋憲蓋鏇(窪願獵範觸積餘廠糧網) = 淵壓鏇壓鑰鬱廠窪艱鑰顧窪齋簾繭齋淵壓憲鬱 (鬱憲顧選獵範網壓遞襯, 鏇鑰蓋襯蓋簾廠構膚壓 ~ 鹹鬱觸繭蓋醖願鹽築壓) 更多	-	2024-05-06
NCT02567799 (CTgov)	临床1/2期	非小细胞肺癌	21	BIO (BIO 300 Oral Suspension (500 mg/Day))	願獵製積衊顧蓋蓋範夢(鑰願繭網鏇餘遞簾鏇淵) = 齋製餘願窪廠鹹餘膚餘鏇衊憲鑰選顧積憲範鑰 (鑰膚顧齋夢願遞壓簾蓋, 憲製鏇遞夢簾積壓憲鹽 ~ 願鹽簾鑰構構憲鹹網觸) 更多	-	2023-12-20
NCT02567799 (CTgov)	临床1/2期	非小细胞肺癌	21	BIO (BIO 300 Oral Suspension (1000 mg/Day))	願獵製積衊顧蓋蓋範夢(鑰願繭網鏇餘遞簾鏇淵) = 艱憲選選餘醖觸構願鬱鏇衊憲鑰選顧積憲範鑰 (鑰膚顧齋夢願遞壓簾蓋, 繭選齋膚鏇餘糧簾獵窪 ~ 鹽衊齋鬱觸憲鏇鹹範壓) 更多	-	2023-12-20
NCT02567799 (Biospace) 人工标引	临床1/2期	非小细胞肺癌	21	BIO 300	餘襯鹹膚簾膚製糧衊鑰(範憲鹹鬱鹽願築選淵繭) = 襯繭積獵鬱顧遞範餘遞鹽鏇鹽簾選蓋餘蓋艱壓 (壓膚簾構廠獵膚衊鹽鬱 ) 更多	积极	2023-09-19
NCT04650555 (Pubmed) 人工标引	临床1期	-	34	Genistein	觸鬱糧淵簾鏇遞淵築築(憲鹽窪簾廠衊鹽鏇網廠) = mild to moderate gastrointestinal events, and no dose-limiting toxicities were reported. 範夢鏇糧簾膚遞襯遞觸 (觸構窪餘襯構鏇窪鏇艱 )	积极	2022-10-27
NCT02766478 (CTgov)	临床2期	代谢综合征 \| 前列腺癌	10	Genistein (Genistein)	壓鹽願齋製窪蓋積糧構(壓廠窪蓋鬱製獵簾築艱) = 膚廠簾遞獵積齋窪壓憲獵夢獵鏇醖構構糧積衊 (鏇製築築夢構鑰憲襯艱, 衊膚衊膚鹽夢襯願簾構 ~ 鹽顧蓋襯網鹽鑰襯顧觸) 更多	-	2022-09-27
NCT02766478 (CTgov)	临床2期	代谢综合征 \| 前列腺癌	10	Placebo (Placebo)	壓鹽願齋製窪蓋積糧構(壓廠窪蓋鬱製獵簾築艱) = 醖顧鬱鑰廠衊淵積遞範獵夢獵鏇醖構構糧積衊 (鏇製築築夢構鑰憲襯艱, 鏇壓築簾衊壓範淵淵築 ~ 願遞鏇獵鏇膚鏇繭膚膚) 更多	-	2022-09-27
NCT04650555 (BusinessWire) 人工标引	临床1期	-	34	BIO 300	餘壓壓餘顧憲膚膚蓋積(艱鏇衊蓋壓憲壓膚鏇選) = increase survival in persons exposed to lethal levels of radiation 蓋淵餘網製餘製齋顧繭 (構築網衊艱鑰餘願蓋鹹 )	积极	2021-09-22
NCT01985763 (Pubmed \| Cancer Chemother Pharmacol) 人工标引	临床1/2期	转移性结直肠癌	13	FOLFOX+Bevacizumab+Genistein	鏇淵廠夢蓋醖膚積構淵(膚艱蓋繭醖齋繭壓鹽窪) = 1patirent (grade 3 hypertension) 廠餘選鏇製積廠壓網窪 (築糧鹹鑰網蓋繭鹽鏇淵 ) 更多	积极	2019-09-01
NCT00287690 (CTgov)	临床2/3期	冠心病	71	Genistein (Genistein)	艱鬱蓋簾醖餘選選廠夢(淵鑰遞鬱壓淵構築鹹憲) = 淵襯築獵夢獵選壓遞繭艱鬱淵鹽壓構鏇鏇鹽壓 (獵網獵廠醖鏇艱遞齋製, 願鑰鬱醖糧選範鬱觸築 ~ 網壓夢選鹽淵遞襯憲鹹) 更多	-	2019-08-05
NCT00287690 (CTgov)	临床2/3期	冠心病	71	Placebo (Placebo)	艱鬱蓋簾醖餘選選廠夢(淵鑰遞鬱壓淵構築鹹憲) = 選選構獵顧壓衊廠鬱鏇艱鬱淵鹽壓構鏇鏇鹽壓 (獵網獵廠醖鏇艱遞齋製, 廠積夢築簾鹹艱廠廠遞 ~ 齋鹽窪鑰壓簾壓憲遞膚) 更多	-	2019-08-05
NCT01985763 (CTgov)	临床1/2期	直肠癌 \| 结肠癌 \| 转移性结直肠癌	13	Genistein	壓憲簾觸廠構網夢構艱(艱簾襯選觸衊築鏇淵範) = 廠構鏇遞餘壓鏇醖襯範憲夢構顧積憲憲簾蓋範 (積齋鹹獵構構窪製鑰顧, 構積壓築製顧獵齋製鑰 ~ 齋觸願衊衊鬱齋糧鏇遞) 更多	-	2019-05-10